TPX Related Analyst PT Change
-
UBS Cuts Estimates and Price Target on Mattress Firm Holding Corp. (MFRM); Might Need Some Tylenol PM
-
Goldman Sachs Chops PT and Estimates on Tempur-Pedic (TPX); From Growth to Value
-
Wedbush Downgrades Tempur-Pedic (TPX) to Neutral; Cutting Numbers and Removing From Best Ideas List
-
Oppenheimer Reiterates Buy, Reduces Price Target on Tempur-Pedic (TPX)
-
Piper Jaffray, Oppenheimer Say Buy the Dip in Tempur-Pedic (TPX); Shares Up 7%
-
Barclays Takes More Conservative Tone on Tempur-Pedic (TPX); Cutting Price Target As Competitive Forces Change
-
Stephens Downgrades Tempur-Pedic (TPX) to Equal Weight
-
Goldman Sachs Cuts Price Target on Tempur-Pedic (TPX) After Guidance Not Raised
-
KeyBanc Maintains a 'Buy' on Tempur-Pedic (TPX); Raising Numbers After Positive Channel Checks
-
Wedbush Reiterates an 'Outperform/Best Idea' on Tempur-Pedic (TPX); See Further Upside
-
Shares of Tempur-Pedic (TPX) Tap New 52-wk High; Barclays Highlights Investor Day
-
KeyBanc Raises Price Target on Tempur-Pedic (TPX) Ahead of Analyst Day on February 22
Back to TPX Stock Lookup
